Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02884102 | MMRF Molecular Profiling Protocol | unknown | — | 1,000 | Multiple Myeloma Research FoundationOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT03225417 | Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | unknown | Phase 1 / Phase 2 | 142 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT05190653 | Early Integration of Palliative and Supportive Care in Cellular Therapy(PALS_CT) | unknown | N/A | 152 | Alberta Health Services, CalgaryOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03942224 | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma(DeRIVE) | unknown | Phase 2 | 49 | Emory UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05422027 | Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 42 | Xia ZhongjunOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06457464 | Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients | unknown | — | 100 | Assiut UniversityOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT05493800 | Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT(Capella) | unknown | Phase 2 | 60 | MitoImmune TherapeuticsINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT03188172 | MUK Nine b: OPTIMUM Treatment Protocol(MUKnineb) | unknown | Phase 2 | 95 | University of LeedsOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT03292263 | ASCT With Nivolumab in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT04499339 | A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | Wuerzburg University HospitalOTHER | 3 | Apr 25, 2024 | clinicaltrials |
| NCT06189833 | Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS(TAURUS) | unknown | Phase 2 | 200 | Stichting European Myeloma NetworkNETWORK | 5 | Apr 23, 2024 | clinicaltrials |
| NCT06379451 | An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma | unknown | Early Phase 1 | 9 | Changzhou No.2 People's HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT05888636 | Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma(TEDROMM) | unknown | — | 200 | Regina Elena Cancer InstituteOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06324266 | Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation | unknown | Phase 2 / Phase 3 | 80 | Jinling Hospital, ChinaOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT05536154 | Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies | unknown | N/A | 68 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05646758 | A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects | unknown | Phase 1 | 140 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06286241 | Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room(Step down ward) | unknown | — | 344 | Siriraj HospitalOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT03975907 | Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) | unknown | Phase 1 / Phase 2 | 121 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06302699 | Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma | unknown | — | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05697913 | Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation | unknown | N/A | 66 | Hospital Galdakao-UsansoloOTHER_GOV | 0 | Mar 6, 2024 | clinicaltrials |
| NCT06242249 | Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06296121 | A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma(DARVIVA) | unknown | Phase 3 | 252 | BiocadINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT03428373 | Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma(RithMM) | unknown | Phase 2 / Phase 3 | 57 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05346198 | Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma | unknown | Phase 1 | 15 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT01754402 | Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Cristina GasparettoOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06258096 | LI-TASTE Study: Light for Taste(LI-TASTE) | unknown | N/A | 52 | Academic Centre for Dentistry in AmsterdamOTHER | 0 | Feb 14, 2024 | clinicaltrials |
| NCT05840107 | Study of FasT CAR-T GC012F Injection NDMM Patients | unknown | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255639 | Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse | unknown | — | 20 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255847 | Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM | unknown | Phase 2 | 43 | Shanxi Bethune HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05478993 | Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement(SPODUMENE) | unknown | Phase 2 | 21 | Peking University People's HospitalOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06223646 | A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 29 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06205823 | Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM(CAREMM-2305) | unknown | — | 1,600 | Seoul St. Mary's HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06203145 | A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM | unknown | N/A | 30 | Peking University First HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05308875 | Efficacy and Safety Evaluation of PD1-BCMA-CART | unknown | N/A | 9 | Bioray LaboratoriesINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04714827 | Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04727008 | CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma | unknown | Phase 1 | 12 | Sichuan UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04877275 | ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | unknown | Phase 2 | 50 | Chunyan Sun, MDOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT06154317 | Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM) | unknown | — | 30 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 118 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | unknown | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05998928 | A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy | unknown | Phase 2 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06126237 | A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 120 | Keymed Biosciences Co.LtdINDUSTRY | 0 | Nov 13, 2023 | clinicaltrials |
| NCT06116734 | Lapelga vs Gastrofil | unknown | Phase 3 | 74 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Nov 3, 2023 | clinicaltrials |
| NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | unknown | Phase 1 | 22 | OncotherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 108 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT05378971 | Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma | unknown | N/A | 15 | LanZhou UniversityOTHER | 1 | Oct 4, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 6, 2025source: clinicaltrials